Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Donny Xu
Advertisement
Donny Xu serves as a policy analyst at RTW Institute, where he researches health policy issues relating to patient access barriers, the global drug innovation landscape, and rare diseases. Prior to joining RTW Institute, Xu supported Verité’s CUMULUS project, conducting due diligence on global labor migration and ethical recruitment systems across Asia. He earned his Master of Public Policy from Georgetown University’s McCourt School of Public Policy and holds a B.A. in Economics and Political Science from the University of Michigan.
Articles by Donny Xu
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5